Loss of the von Hippel-Lindau (VHL) tumor suppressor gene contributes to proliferative disorders including renal cell carcinoma. The consequence of VHL loss is increased levels of hypoxia-inducible factor-a (HIFa), which is targeted for proteolytic degradation by the VHL gene product pVHL. HIF is a transcription factor that increases the expression of factors critical for tumorigenesis in renal cell carcinoma. We report here another regulatory component of HIFa expression in renal cancer cells. Phospholipase D (PLD), which is commonly elevated in renal and other cancers, is required for elevated levels of both HIF1a and HIF2a in VHL-deficient renal cancer cells. The induction of both HIF1a and HIF2a by hypoxic mimetic conditions was also dependent on PLD in renal cancer cells with restored pVHL expression. The effect of PLD activity upon HIFa expression was at the level of translation. PLD activity also provides a survival signal that suppresses apoptosis induced by serum deprivation in the renal cancer cells. Suppression of HIF2a has been shown to reverse tumorigenesis with renal cancer cells. The finding here that HIF2a expression is dependent on PLD in renal cancer cells suggests that targeting PLD signals may represent an alternative therapeutic strategy for targeting HIF2a in renal cancers where HIF2a is critical for tumorigenesis and elevated PLD activity is common.
Introduction
Loss of the von Hippel-Lindau (VHL) gene results in a variety of pathologies-most significantly renal cell carcinoma (Maynard and Ohh, 2004; Kaelin, 2007) . The VHL gene product pVHL is part of an E3 ubiquitin ligase complex that targets the a subunits of hypoxia-inducible factor (HIFa) for degradation by the proteasome in the presence of O 2 (Ohh, 2006) . The level of HIFa is regulated by proline hydroxylation, which tags HIFa for recognition by pVHL when O 2 is present (Kaelin, 2005) . In the absence of pVHL, there is an upregulation of HIFa and this elevated expression of HIFa has been strongly implicated in VHL disease and renal cell carcinoma (Maynard and Ohh, 2004; Kaelin, 2007) . HIFa dimerizes with HIFb to form a transcription factor that stimulates the transcription of genes that regulate angiogenesis and other factors important for responding to hypoxic conditions such as vascular endothelial growth factor (VEGF) and glycolytic enzymes (Shaw, 2006) . There are several different a subunits-two of which have been implicated in tumorigenesis. The expression of HIF1a and HIF2a is frequently elevated in a variety of cancers (Maynard and Ohh, 2004) . HIF1a has been reported to both promote and suppress tumor progression, whereas HIF2a has been implicated only in tumor promotion (Gordan and Simon, 2007) . The somewhat overlapping and antagonistic effects of HIF1a and HIF2a are poorly understood, but it is clear that in renal cell carcinoma, HIF2a is a critical factor-in that suppression of HIF2a blocks tumor formation by renal cancer cells (Kondo et al., 2002 (Kondo et al., , 2003 . It is believed that the elevated expression of HIF2a contributes to the survival signals in renal cancer cells that protect from apoptosis and facilitate angiogenesis.
It has become apparent in recent years that a critical hurdle in tumorigenesis is the generation of survival signals that suppress default apoptotic programs (Hanahan and Weinberg, 2000) . Phospholipase D (PLD), which has been shown to provide survival signals in human cancer cells (Foster, 2006) , has been reported to be elevated in many human cancers including renal cell carcinoma (Zhao et al., 2000) . Elevated PLD activity has been reported to contribute to the activation of Raf (Rizzo et al., 1999) , mitogen-activated protein (MAP) kinase (Shen et al., 2001) , mTOR (Fang et al., 2001; Foster, 2007) and increase Myc expression )-all of which have been implicated in survival signals in cancer cells. PLD has also been reported to suppress expression of p53 (Hui et al., 2004) and the activity of protein phosphatase 2A (Hui et al., 2005) -both of which have been implicated in tumor suppression. Thus, PLD activity has been implicated in many prosurvival and proliferation signals that have been implicated in many human cancers.
We report here that expression of HIF2a, at the level of translation, in VHL-deficient renal cancer cell lines is dependent on PLD activity. This study provides evidence of a VHL-independent mechanism for HIF2a expression and suggests that targeting PLD signals may represent a novel strategy for treating renal and other cancers where survival is dependent on both PLD and HIF2a.
Results

PLD activity is elevated in kidney cancer cell lines
Since elevated PLD activity has been reported in human kidney cancer (Zhao et al., 2000) , we examined the level of PLD activity in the well-characterized renal cell carcinoma cell lines 786-O and RCC4. We previously reported that there are highly elevated levels of PLD activity in the MDA-MB-231 human breast cancer cell line relative to MCF-7 human breast cancer cells (Zhong et al., 2003; Chen et al., 2005) . The level of PLD activity in the 786-O cells was compared with the level of PLD activity in MDA-MB-231 and MCF-7 cells. We also examined the PLD activity in the immortalized human embryonic kidney cell line HEK293. As shown in Figure 1a , the level of PLD activity in both the 786-O and RCC4 cells was comparable to the level of PLD activity in the MDA-MB-231 cells and substantially higher than the PLD activity in the MCF-7 and HEK293 cells. These data demonstrate that consistent with the report indicating elevated PLD activity in kidney tumors (Zhao et al., 2000) , both the 786-O and RCC4 kidney cancer cell lines also have high levels of PLD activity.
We next examined the expression levels of PLD1 and PLD2 protein in the 786-O and RCC4 renal cancer cells relative to the levels observed in HEK293, MDA-MB-231 and MCF-7 cells using western blot analysis. As shown in Figure 1b , there were relatively high levels of PLD1 expression in all three kidney-derived cell lines relative to the breast cancer cell lines. There also appeared to be lower levels of PLD2 expression in the kidney cell lines relative to the breast cancer cell lines. Importantly, there were no significant increases in the expression in PLD1 or PLD2 in the 786-O and RCC4 cells relative to the HEK293 cells that could explain the increased activity. We also examined the level of PLD activity and protein in 786-O cells where expression of pVHL had been restored Ohh et al., 1998) . As shown in Figures 1a and b , restoring pVHL expression did not have significant effect upon either the activity expression levels of PLD isoforms. Thus, the increased PLD activity in the 786-O cells was not likely due to the loss of VHL expression.
Survival of 786-O cells deprived of serum is dependent on PLD activity
We reported previously that PLD activity is critical for the survival of breast cancer cells when subjected to the stress of serum withdrawal . We therefore examined the effect-suppressing PLD-mediated production of phosphatidic acid (PA) on 786-O cells deprived of serum. To suppress PA production, we treated 786-O cells with the primary alcohol 1-butanol (1-BtOH), which results in the formation of phosphatidylbutanol instead of PA by PLD (Shen et al., 2001) . As shown in Figure 2a , in the absence of serum, 1-BtOH caused a loss in cell viability and an increase in cleavage of the caspase-3 substrate poly-(ADP-ribose) polymerase (PARP), indicating that the cells were undergoing apoptosis. PARP cleavage was not observed with the tertiary alcohol t-BtOH, which is not a substrate for PLD (Shen et al., 2001) . To further establish that the effect observed with 1-BtOH was due to suppressing the production of PLD-induced PA, we examined the effect of reducing the expression of PLD1 and PLD2 in 786-O cells with siRNA. The 786-O cells were transfected with siRNA for PLD1 and PLD2 individually and together. PARP cleavage was then determined in the presence and . Cells were put into media containing 0.5% serum overnight prior to performing the assay. PLD activity was determined using the transphosphatidylation reaction and the levels of phosphatidylbutanol (PBt) were determined using thinlayer chromatography as described in 'Materials and methods'. The PBt band from a thin-layer chromatograph is shown in the inset. The relative levels of PLD activity were obtained by normalizing to the level of PLD activity in the MCF-7 cells, which was given a value of 1. The experiment shown is representative of at least three independent experiments. (b) The relative levels of PLD1 and PLD2 protein in the cells evaluated in (a) were determined by western blot. The data shown are representative of an experiment repeated two times.
Dependence of HIFa expression on phospholipase D A Toschi et al absence of serum. As shown in Figure 2b , the PLD1 and PLD2 siRNAs were effective in reducing the levels of PLD1 and PLD2 protein. Also shown is that suppression of either PLD1-or PLD2-enhanced PARP cleavage in the absence of serum, but not in the presence of serum ( Figure 2b ). Using both PLD1 and PLD2 siRNAs together increased PARP cleavage. These data indicate that PLD activity is providing a survival signal in the 786-O cells that suppresses apoptosis under conditions of serum withdrawal. Similar data were obtained with RCC4 renal cancer cells (data not shown)-indicating that the elevated PLD activity in these cells also provides a survival signal in these cells as well. The data presented also suggest that both PLD1 and PLD2 are contributing to the survival of 786-O cells under conditions of serum withdrawal.
HIF2a expression in renal cancer cells is dependent on PLD
A consistent genetic defect in kidney cancer is the loss of the VHL gene, which results in increased levels of HIF2a (Maynard and Ohh, 2004) . HIF2a is a transcription factor that stimulates the expression of genes that contribute to angiogenesis, proliferation and survival (Maynard and Ohh, 2004; Hickey and Simon, 2006) . PLD has also been implicated in cell proliferation and survival (Foster and Xu, 2003; Foster, 2006) and the induction of HIF1a in MDA-MB-231 cells (Zheng et al., 2006) . Similarly, HIF2a has been shown to be critical for tumor formation by 786-O cells (Kondo et al., 2002 (Kondo et al., , 2003 . Since PLD activity was critical for the survival of 786-O cells, we examined whether elevated HIF2a expression in the pVHL-deficient 786-O cells was dependent on PLD activity. As shown in Figure 3a , 1-BtOH, but not t-BtOH, suppressed HIF2a expression in 786-O cells. We also examined the induction of HIF2a by hypoxia-mimetic conditions generated by CoCl 2 in 786-O cells where the VHL gene had been reintroduced Ohh et al., 1998) . As expected, restoration of pVHL expression eliminated HIF2a stabilization under normoxic conditions ( Figure 3b ). However, when cells were treated with CoCl 2 , HIF2a accumulation was observed, and importantly, the induction of HIF2a expression by CoCl 2 was prevented by 1-BtOH, but not by t-BtOH. We also examined the effect of PLD1 and PLD2 siRNA on HIF2a expression, and as shown in Figure 3c , both PLD1 and PLD2 siRNA suppressed HIF2a in 786-O cells, and PLD1 and PLD2 siRNA together completely abolished HIF2a expression. The effect of the PLD siRNAs on PLD activity is also shown in Figure 3c , where it can be seen that the effect on PLD activity correlates with the effect on HIF2a expression. Similar data were obtained using catalytically inactive dominant-negative mutants for PLD1 and PLD2 (data not shown). These data reveal that HIF2a expression is dependent on PLD activity in the VHL-deficient kidney cancer cell line 786-O. The data also demonstrate that when the VHL gene is restored and HIF2a is induced by hypoxic mimetic conditions, there is still a dependence on PLD activity for HIF2a expression.
Suppression of PLD activity has no effect on HIF2a transcription, but suppresses gene expression mediated by HIF While the data presented above reveal that PLD activity is required for the expression of HIF2a, it does not reveal at what level it is required. We, therefore, examined the effect of 1-BtOH and t-BtOH on the levels of HIF2a RNA. As controls, we also examined the effect on the levels of tubulin and VEGF RNA. The expression of HIF2a leads to the transcriptional activation of several genes involved in angiogenesis including VEGF (Hickey and Simon, 2006) . As shown in Figure 4a , 1-BtOH had no effect upon the level of HIF2a RNA, but did suppress the level of VEGF RNA. Dependence of HIFa expression on phospholipase D A Toschi et al
As expected, there was no effect of 1-BtOH upon tubulin RNA. We also examined the effect of 1-BtOH on the induction of HIF2a in the 786-O cells with restored expression of pVHL. As shown in Figure 4b , upon treatment with hypoxic mimetic conditions, there was an increase in the level of VEGF RNA, but no change in either HIF2a or tubulin RNA. The induction of VEGF RNA was blocked by 1-BtOH, but not t-BtOH. We also examined the effect of catalytically inactive PLD mutants of both PLD1 and PLD2 that act as dominant-negative mutants (Shen et al., 2001) on the levels of HIF2a, VEGF and tubulin RNA. As shown in Figure 4c , the dominant-negative PLD mutants reduced the levels of PLD activity and HIF2a protein. As was observed with the PLD siRNA effect on HIF2a expression, transfection with mutants for both PLD1 and PLD2 had a greater effect than either of the PLD mutants by themselves. As observed with 1-BtOH, the dominant-negative PLD mutants had no effect upon HIF2a RNA, but did suppress the level of VEGF RNA. These data further establish that HIF2a expression is dependent on PLD activity, and importantly, show that the effect of PLD on HIF2a expression is not at the level of transcription.
The dependence of HIF2a expression on PLD is at the level of translation The data in Figure 4 indicate that the effect of PLD on HIF2a expression is not due to increased transcription. We next investigated whether PLD affected the stability and half-life of HIF2a. To accomplish this, we examined whether the suppression of PLD activity could be reversed by a variety of protease inhibitors. We also investigated the effect of suppressing of PLD activity on the half-life of HIF2a. These data revealed that the dependence of HIF2a expression on PLD activity was not due to changes in the stability of HIF2a ( Supplementary Figures 1 and 2 ). We next examined whether the effect of PLD on HIF2a was at the level of translation. To determine whether PLD impacted on HIF2a translation, we used the 786-O cells with restored expression of pVHL. In these cells HIF2a expression is not detected because, in the presence of O 2 , HIF2a is ubiquitinated and degraded by the proteasome (Ohh, 2006) . If these cells are treated with the proteasome inhibitor MG132, there is an increase in HIF2a that is blocked by cyclohexamide, which inhibits protein synthesis ( Figure 5) . Thus, the increase in HIF2a observed in the presence of the proteasome inhibitor is due to translation. We then examined the effect of 1-BtOH on the translation of HIF2a and as shown in Figure 5 , 1-BtOH, like cyclohexamide, completely suppressed HIF2a expression. These data indicate that the effect of PLD in HIF2a expression is at the level of translation.
Both HIF1a and HIF2a expression in RCC4 cells are dependent on PLD activity As indicated in Figure 1 , RCC4 kidney cancer cells also have elevated PLD activity. Whereas the 786-O cells have elevated expression of HIF2a, the RCC4 cells have elevated expression of both HIF2a and HIF1a (Figure 6a ). We reported previously that elevated expression of HIF1a in MDA-MB-231 cells was dependent on PLD activity (Zheng et al., 2006) . We, therefore, Figure 2 and HIF2a levels were determined 72 h later by western blot analysis. PLD1 and PLD2 levels were also evaluated by western blot. The PLD activity as determined by the generation of phosphatidylbutanol (PBt) in cells transfected with PLD1 and PLD2 siRNAs was evaluated as in Figure 1a . Experiments shown are representative of experiments repeated at least two times.
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examined whether the expression of HIF1a and HIF2a in RCC4 cells was dependent on PLD activity. As shown in Figure 6b , 1-BtOH suppressed both HIF1a and HIF2a in the RCC4 cells. We also examined the induction of HIF1a by hypoxia-mimetic conditions generated by CoCl 2 in RCC4 cells where the VHL gene had been reintroduced Ohh et al., 1998) . As shown in Figure 6c , restoration of pVHL expression eliminated HIF1a expression. However, when cells were treated with CoCl 2 , HIF2a expression was restored and importantly, the induction of HIF1a expression by hypoxia-mimetic CoCl 2 was also prevented by 1-BtOH, but not by t-BtOH. These data indicate that both HIF1a and HIF2a are dependent on PLD activity. We next examined whether the impact of PLD on HIF1a, like HIF2a, is at the level of translation. RCC4 cells with reintroduced pVHL expression were treated with MG132 to increase expression of HIF1a and then treated with either cyclohexamide or 1-BtOH as in Figure 5 . Both cyclohexamide and 1-BtOH prevented the increase in HIF1a expression induced by suppression of the proteasome with MG132 (Figure 6d) . Thus, like HIF2a, the effect of PLD on HIF1a expression is at the level of translation.
Discussion
HIFa expression is elevated as a response to stressful conditions that warrant enhanced angiogenesis and blood supply (Hickey and Simon, 2006) . In the presence and PLD2 as indicated. HIF2a and VEGFa RNA levels were determined 24 h later as in (a). PLD activity levels were determined by the transphosphatidylation reaction as in Figure 1 . The PLD mutants were tagged with hemagglutinin (HA; Colley et al., 1997) and the expression levels of the PLD mutants were determined by western blot using an anti-HA antibody. The levels of HIF2a protein and actin were also determined by western blot. Experiments shown are representative of experiments repeated at least two times. Figure 5 Inhibition of PLD prevents hypoxia-inducible factor (HIF)2a protein translation. 786-von Hippel-Lindau (VHL) cells were plated and shifted to media without serum for 16 h. The cells were then treated for the indicated times with the proteasome inhibitor MG132 (100 mM) alone or concomitant with the translation inhibitor cyclohexamide (CHX) (100 mM) or 1-butanol (1-BtOH, 0.8%) as indicated. HIF2a levels were determined at the indicated times by western blot analysis. The data shown are representative of two independent experiments.
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A Toschi et al of O 2 , HIFa is hydroxylated and targeted by pVHL for ubiquitination and subsequent degradation by the proteasome (Kaelin, 2005; Ohh, 2006) . In the absence of pVHL, HIFa is stabilized under normoxic conditions and stimulates the expression of several genes implicated in the survival of cancer cells and tumorigenesis (Maynard and Ohh, 2004; Gordan and Simon, 2007; Kaelin, 2007) . We recently reported that in response to the stress of serum withdrawal in culture, there is a substantial increase in PLD activity in several cancer cell lines (Zheng et al., 2006) . Thus, elevated PLD activity also represents a stress response that some cancer cells have adapted to promote survival in the absence of serum growth factors. Upon serum withdrawal, the survival of the renal cancer cells used in this study was also dependent on PLD. Stable expression of HIF2a is a critical aspect of tumorigenesis in renal cell carcinoma (Maxwell, 2005; Kaelin, 2007) . The evidence provided here reveal that the expression of both HIF1a and HIF2a is dependent on the elevated levels of PLD activity in two renal cancer cells lacking pVHL. The PLD requirement was at the level of translation. Upon restoration of pVHL expression, hypoxic mimetic induction of HIFa was also dependent on PLD activity. Both PLD1 and PLD2 seem to be involved in that suppression of both PLD1 and PLD2 reduced HIF2a expression. We have proposed previously that the activation PLD1 leads to increased PLD2 activity (Foster and Xu, 2003; Foster, 2006) , and we have shown that both PLD1 and PLD2 are required for receptor endocytosis and MAP kinase activation (Shen et al., 2001) . This study reveals that in addition to being regulated at the level of turnover through pVHL, HIFa is also regulated at the level of translation by signals mediated by PLD. Regulation of HIFa at the level of translation was reported recently for suppression of HIFa in response to the promyelocytic leukemia tumor suppressor (Bernardi et al., 2006) . This report, along with data provided here, suggest multiple forms of stress impact upon HIFa expression in renal cancer cells. An emerging theme in tumorigenesis is that cancer cells need to continue proliferate under stressful conditions-such as the hypoxia that occurs early in a solid tumor prior to vascularization (Gatenby and Gillies, 2004) . The expression of HIFa stimulates the expression of genes that promote angiogenesis, glycolysis and anaerobic respiration (Semenza, 2001; Hickey and Simon, 2006) . Thus, elevated HIFa expression in a solid tumor would allow the cells to function better in the absence of O 2 and enhance vascularization so that ultimately O 2 and other nutrients can become available. The lack of serum growth factors also represents a challenge for cells in an emerging solid tumor prior to vascularization. We have found that in several human Dependence of HIFa expression on phospholipase D A Toschi et al cancer cells PLD activity is elevated as a stress response to the removal of serum (Zheng et al., 2006) and that the elevated PLD activity suppresses apoptosis under these conditions . The renal cancer cells used in this study had elevated PLD activity in both the presence and absence of serum (data not shown). Thus, unlike some other cancer cells, the elevated PLD activity is constitutive. A possible explanation for this is that HIFa expression is needed constitutively in renal cell carcinoma and therefore a constitutive elevation of PLD activity is needed to maintain the translation of HIFa. Kaelin and colleagues have reported that suppressing HIF2a is sufficient to prevent tumorigenesis (Kondo et al., 2002 (Kondo et al., , 2003 . It is currently not practical to suppress the expression of a protein as a therapeutic strategy in most cancers. It is also not practical to reintroduce a lost protein such as VHL back into a cancer cell. The finding here that PLD is required for the expression of both HIF1a and HIF2a suggests that targeting PLD represents a promising therapeutic strategy in cancers such as renal cancer where there is both a dependence upon HIFa for tumorigenesis and a reported high incidence of elevated PLD activity (Zhao et al., 2000) . While there are no drugs available that target PLD specifically, there is potential for targeting the signals that activate PLD or the downstream targets of PLD-generated PA. The data in Figure 1 indicate that the elevated PLD activity in the cancer cell lines used in this study was not due to elevated expression of either PLD1 or PLD2. Thus, there should be elevated signals that lead to increased PLD activity that could be targeted. There are also several downstream targets of PLD that might be similarly targeted. The potential for targeting PLD in cancer cells was recently reviewed (Foster, 2006) . It will be critical to identify the critical upstream effector signals that activate PLD and the downstream targets of PLD that lead to the expression of HIFa. An especially attractive target of PLD signaling is mTOR-the mammalian target of rapamycin, since rapamycin is a highly specific drug and mTOR has been implicated in the translation of proteins implicated in cell survival (Sawyers, 2003; Foster, 2004) and is activated by PA (Fang et al., 2001; Chen et al., 2003; Foster, 2007) . Preliminary studies indicate that it may be complicated in that rapamycin suppresses HIF1a very efficiently, while having little effect on HIF2a expression (our unpublished results). Intriguingly, HIF2a seems to be dependent on the rapamycin-insensitive mTORC2. While the signals mediated by PLD required for HIFa expression need to be further elaborated, data presented here make it clear that targeting PLD-mediated signals could be a viable strategy for treating cancers that are dependent on HIFa.
Materials and methods
Cells, cell culture conditions and transfection MCF-7, MDA-MB-231, HEK293, RCC4 and 786-O cells were obtained from the American Type Culture Collection. The 786-VHL and RCC4-VHL cells were generated as described previously (Stickle et al., 2004) . All cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. Transfections were carried out using Lipofectamine LTX reagent (Invitrogen, Carlsbad, CA, USA) according to the vendor's instructions. Transfection efficiency was determined by transfection of pEGFP-C1 (Clontech, Mountain View, CA, USA), which expresses green fluorescent protein. The percentage of green cells was determined microscopically and was routinely in excess of 90%.
Materials
CoCl 2 and cyclohexamide were obtained from Sigma-Aldrich (St Louis, MO, USA). Antibodies to PARP (human specific) and PLD1 were obtained from Cell Signaling (Danvers, MA, USA). Antibodies to HIF1a were obtained from BD Biosciences (San Jose, CA, USA). Antibodies against HIF2a, actin, ubiquitin, glyceraldehyde-3-phosphate dehydrogenase (GADPH) and hemagglutinin (HA) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). [ 3 H]-myristic acid was obtained from PerkinElmer (Waltham, MA, USA). Precoated silica 60 A thin-layer chromatography plates were from Whatman (Hillsboro, OR, USA). The proteasome inhibitors (MG132, lactacystin, PSI and epoxomycin), the lysosome inhibitors (bafilomycin, chloroquine, concanamycin and NH 4 Cl) and the calpain inhibitors (ALLN, Z-L-L-CHO and ALLM) were obtained from EMD Biosciences (San Diego, CA, USA). siRNAs targeting PLD1, PLD2 and GADPH were obtained from Ambion (Austin, TX, USA).
Plasmids
The pcDNA3.1 control plasmid was obtained from Invitrogen. The plasmid expression vector for catalytically inactive PLD1 and PLD2 mutants (pCGN-PLD1-K898R and pCGN-PLD2-K758R) were generous gifts from Dr Michael Frohman (SUNY, Stony Brook, NY, USA).
Phospholipase D assays
Cells were plated in 60 mm culture dish at 4 Â 10 5 cells per dish. The next day, cells were made quiescent by shifting into DMEM containing 0.5% bovine calf serum for overnight. Cells were then prelabeled for 4 h with [ 3 H]-myristate (3 mCi, 40 Ci mmol À1 ) in 3 ml of medium. PLD catalysed transphosphatidylation in the presence of 0.8% 1-BtOH, and the extraction and characterization of lipids by thin-layer chromatography was performed as described previously (Shen et al., 2001) .
Cell viability and apoptosis assays Cell viability was determined by Trypan blue exclusion (Sigma-Aldrich). After various treatments, cells were harvested, washed and treated with Trypan blue at a concentration of 0.4% w/v. After 10 min, Trypan blue uptake (dead cells) was determined by counting on a hemocytometer.
Western blot analysis
Extraction of proteins from cultured cells and western blot analysis of extracted proteins were carried out using the ECL system (Amersham, Piscataway, NJ, USA) as described (Shen et al., 2001) .
RNA analysis
Total RNA was purified from cells using the RNeasy RNA isolation Kit (Qiagen, Valencia, CA) using the manufacturer's protocol. RNA (2 mg) was reverse transcribed then amplified for 35 cycles using the Qiagen OneStep RT-PCR Kit according to the manufacturer's instructions. PCR was carried out with the following primers: VEGFa, HIF2a and b-tubulin (Qiagen). PCR products were visualized by electrophoresis using 2% agarose E-gels (Invitrogen).
siRNA Cells were plated on 12-well plates at 30% confluence in medium containing 10% serum without antibiotics. After 1 day, cells were transfected with siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's directions. After 24 h the media was changed to fresh media containing 10% serum. After 3 days cells were lysed and analysed by western blot.
